Pharmacy Programs: Manufacturer Assistance, Discount Cards, 340B Access, and Every Dollar Left on the Table

Series 10, Article 06

The pharmacy benefit in a small group level funded plan operates on a simple premise: the PBM negotiates rates, the pharmacy dispenses, the plan pays. This transaction-focused model misses billions of dollars in manufacturer assistance, discount programs, and 340B pricing that flow around the PBM-mediated transaction and never reach the plan. A TPA that builds systematic pharmacy cost recovery captures value that most plans leave entirely on the table.

Manufacturer patient assistance programs provide free or reduced-cost medications to qualifying patients. Copay assistance cards reduce member out-of-pocket costs, sometimes with complex plan-level interactions. Pharmacy discount programs provide point-of-sale savings outside the PBM network. 340B drug pricing offers discounts of 25% to 50% for covered entities and their contract pharmacies. None of these programs operate automatically. All require infrastructure to identify eligible members, enroll them, and capture the savings systematically.

Manufacturer Patient Assistance Programs

#

Pharmaceutical manufacturers operate patient assistance programs (PAPs) as part of their patient access strategies. The programs provide free or reduced-cost medications to patients who meet income and insurance criteria. The scale is substantial: AbbVie’s myAbbVie Assist program alone served more than 235,000 patients in 2024 (“Patient Assistance | AbbVie”).

Eligibility criteria vary by manufacturer but follow consistent patterns. Most programs require US citizenship or legal residency, household income at or below 300% to 400% of the Federal Poverty Level, limited or no insurance coverage for the specific medication, and ineligibility for government programs like Medicaid or VA benefits. For 2024, 400% of FPL for a household of one was approximately $58,320; for a household of four, approximately $120,000. These thresholds extend eligibility well into the middle class.

The savings for qualifying patients are substantial. A patient on Humira (adalimumab) at a list price exceeding $80,000 per year who qualifies for AbbVie’s PAP receives the medication at no cost. A patient on Ozempic at $12,000 per year who qualifies for Novo Nordisk’s PAP receives the medication at no cost. The programs eliminate the member’s out-of-pocket cost and, in some program structures, eliminate the plan’s cost as well.

NeedyMeds, a nonprofit clearinghouse for patient assistance information, lists more than 400 PAPs from pharmaceutical manufacturers. The programs cover the majority of high-cost brand-name and specialty medications. The infrastructure for identifying programs exists; what most small plans lack is the systematic process for identifying eligible members and enrolling them.

The enrollment process requires prescriber involvement. Most PAPs require a signed application from both patient and prescriber confirming diagnosis, income eligibility, and insurance status. Approval timelines range from 10 to 30 business days. Medications are typically shipped to the prescriber’s office rather than the patient’s home. Renewal is required annually, with income reverification.

For a small group plan, systematic PAP enrollment recovers costs that would otherwise flow through the claims fund. A member on a $100,000 specialty drug who qualifies for PAP removes that $100,000 from plan expense entirely. The TPA’s role is member identification (using claims data to flag high-cost drug utilization), eligibility screening (assessing income and insurance status against program criteria), and enrollment support (assisting members and prescribers with application completion).

Copay Assistance and Accumulator Programs

#

Manufacturer copay assistance cards reduce member out-of-pocket costs for branded medications. The programs are ubiquitous for high-cost drugs: virtually every branded specialty medication has an associated copay card program. The cards pay a portion or all of the member’s copay, reducing the perceived cost of expensive medications and encouraging adherence.

The plan-level interaction with copay assistance has become contentious. Under traditional benefit design, manufacturer copay assistance counted toward the member’s deductible and out-of-pocket maximum. The manufacturer paid, but the payment advanced the member toward their cost-sharing limits. Once limits were reached, the plan covered the medication at 100%.

Copay accumulator programs changed this dynamic. Under an accumulator design, manufacturer copay assistance does not count toward the member’s deductible or out-of-pocket maximum. The manufacturer’s payment covers the immediate cost, but the member remains responsible for meeting their cost-sharing limits through actual out-of-pocket spending. The practical effect: members on high-cost drugs exhaust manufacturer assistance early in the year and then face the full cost-sharing burden, sometimes thousands of dollars.

Copay maximizer programs operate differently. Under a maximizer design, the plan extracts the maximum available manufacturer assistance by structuring copays to match the available assistance amount. The manufacturer pays more, the member pays nothing, and the plan captures the manufacturer’s contribution toward benefit expense.

The legal landscape is shifting. As of late 2025, 25 states, the District of Columbia, and Puerto Rico have enacted legislation restricting or banning copay accumulator programs for state-regulated health plans (Avalere Health). These laws require that manufacturer copay assistance count toward member cost-sharing limits, effectively eliminating accumulator programs in the regulated market. Approximately 17% of the total US commercial market (roughly 34 million individuals) is now enrolled in plans that must count copay assistance toward cost-sharing limits.

For self-funded ERISA plans, the legal picture is more complex. ERISA preemption may shield self-funded plans from state accumulator bans. Iowa’s SF 383 marked the first attempt to enforce a state accumulator ban against the self-funded market; a federal judge promptly granted an injunction, finding the law likely preempted by ERISA. The litigation continues, but self-funded plans currently retain more flexibility than fully insured plans in accumulator program design.

The policy decision for a TPA advising plan sponsors is nuanced. Accumulator programs reduce plan cost but shift burden to members, potentially affecting drug adherence and employee satisfaction. Maximizer programs extract manufacturer value without shifting burden to members but require more complex administration. The choice depends on plan sponsor philosophy about cost-sharing design and member relations.

Discount Programs and 340B Access

#

Pharmacy discount programs operate outside the PBM-mediated benefit structure. GoodRx, RxSaver, and comparable services negotiate pricing directly with pharmacies and offer that pricing to consumers at point of sale. The discount card replaces insurance billing; the member pays cash at the discounted rate.

For many generic and some branded medications, discount card pricing beats PBM-negotiated pricing. The differential reflects PBM spread pricing practices and negotiating leverage variations. A generic medication that costs $15 through the PBM network might cost $4 at a cash price through GoodRx. The savings accrue to the member when they pay cash rather than using their benefit, and to the plan when the discounted cash price is lower than the PBM-negotiated rate.

The TPA opportunity is educating members about when discount card pricing beats plan pricing and designing benefits that encourage intelligent shopping. A plan that reimburses members for cash purchases when cash pricing is lower than network pricing captures savings while maintaining benefit coverage.

340B drug pricing represents a larger and more complex opportunity. The 340B Drug Pricing Program, established in 1992, requires pharmaceutical manufacturers participating in Medicaid to provide outpatient drugs to covered entities at significantly reduced prices. The discounts typically range from 25% to 50% below average wholesale price.

The program has grown dramatically. In calendar year 2024, 340B covered entities purchased $81.4 billion in covered outpatient drugs under the program (HRSA). This represents substantial growth from $66.3 billion in 2023 and $53.7 billion in 2022. The number of covered entity sites has more than tripled from approximately 20,000 in 2012 to more than 60,000 in 2024 (ADVI).

Covered entity types eligible for 340B include federally qualified health centers (FQHCs), FQHC look-alikes, Ryan White clinics, state AIDS drug assistance programs, disproportionate share hospitals (DSH), critical access hospitals, and other safety-net providers. Hospitals account for 87% of total 340B purchases; federal grantees account for the remaining 13%.

Small employer plans cannot directly participate in 340B. The program applies to covered entities, not employer plans. The access pathway is indirect: members who receive care at 340B-eligible entities (FQHCs, critical access hospitals, DSH hospitals) may receive 340B-priced drugs when prescriptions are filled through the entity’s pharmacy or contract pharmacy arrangements.

The practical opportunity for a TPA is limited but real. Identifying members who receive care at 340B-eligible entities and ensuring prescriptions are routed through channels that capture 340B pricing creates savings. The operational complexity is significant: the TPA must track which providers are 340B-eligible, which pharmacies participate in contract pharmacy arrangements, and which prescriptions qualify for 340B pricing.

Systematic Capture as TPA Infrastructure

#

The common thread across these programs is that individual small employers cannot capture the value systematically. PAP enrollment requires identifying eligible members across a small population, navigating complex application processes, and managing renewals. Copay card optimization requires benefit design decisions and ongoing management. Discount program integration requires member education and reimbursement processes. 340B optimization requires provider and pharmacy mapping.

A TPA operating across a book of business can build the infrastructure once and deploy it for every plan. The economics are different at scale. A TPA managing 50 small group plans with 1,000 total members has sufficient population to justify dedicated pharmacy cost recovery infrastructure. An individual 25-person plan does not.

The infrastructure components include: claims data analytics to identify high-cost drug utilization and flag PAP-eligible members; enrollment support services to assist members and prescribers with PAP applications; benefit design consulting to optimize copay assistance capture based on plan sponsor philosophy; discount program integration to educate members and enable cash-price reimbursement when advantageous; and provider and pharmacy mapping to identify 340B access opportunities.

The ROI calculation is favorable. If TPA-level pharmacy cost recovery infrastructure costs $50,000 to build and $25,000 per year to operate across a book of 50 plans, the per-plan cost is approximately $1,500 per year after amortization. If the infrastructure recovers an average of $15,000 per plan in PAP enrollment, copay optimization, and discount capture, the 10:1 return justifies the investment.

For a representative 25-person plan, the savings breakdown might include: two members enrolled in PAPs for specialty drugs, saving $50,000 in plan expense; optimized copay assistance design capturing an additional $5,000 from manufacturer cards; and discount program education resulting in $2,000 in reduced pharmacy claims. Total pharmacy cost recovery: $57,000 against an expected claims fund of $375,000, or 15% of total expected claims.

The TPA that builds this capability competes differently than the TPA that processes claims and passes pharmacy through to the PBM without intervention. The margin structure changes. The value proposition to employers changes. The differentiation from commodity TPA services becomes defensible. Pharmacy cost recovery is not the only lever, but it is a lever that most TPAs leave untouched.